Drug intelligence / Profile preview

TJ-TL23

Development stage: Preclinical
Lead developer: TJ Biopharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

TJ-TL23 is a preclinical-stage bispecific antibody (BsAb) being developed by TJ Biopharma (originally initiated by I-Mab) for the treatment of inflammatory bowel disease (IBD). Engineered using TJ Biopharma's proprietary AntibodyPLUS platform, the therapeutic is designed to simultaneously modulate key inflammatory pathways involved in gut inflammation. Specific molecular targets for TJ-TL23 have not been publicly disclosed.

Beyond the preview

Go deeper on TJ-TL23.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJ-TL23.

Explore the full profile